Patricio Silva-Da
Porto, Portugal
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Correction to: Effectiveness and safety of opicapone in Parkinson's disease patients with motor fluctuations: the OPTIPARK open-label study.
Journal: Translational neurodegeneration
Published: April 30, 2020
Comparative analysis of the safety and tolerability of eslicarbazepine acetate in older (≥60 years) and younger (18-59 years) adults.
Journal: Epilepsy research
Published: March 10, 2020
Effectiveness and safety of opicapone in Parkinson's disease patients with motor fluctuations: the OPTIPARK open-label study.
Journal: Translational neurodegeneration
Published: December 06, 2019
Safety, Tolerability and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy in Patients Aged ≥ 65 Years with Focal Seizures.
Journal: Drugs & aging
Published: November 03, 2018
Effects of adjunctive eslicarbazepine acetate on serum lipids in patients with partial-onset seizures: Impact of concomitant statins and enzyme-inducing antiepileptic drugs.
Journal: Epilepsy research
Published: August 04, 2017
Influence of titration schedule and maintenance dose on the tolerability of adjunctive eslicarbazepine acetate: An integrated analysis of three randomized placebo-controlled trials.
Journal: Epilepsy research
Published: March 03, 2017
Effects of eslicarbazepine acetate on acute and chronic latrunculin A-induced seizures and extracellular amino acid levels in the mouse hippocampus.
Journal: BMC neuroscience
Published: August 03, 2014
Catechol-O-methyltransferase inhibition in erythrocytes and liver by BIA 3-202 (1-[3,4-dibydroxy-5-nitrophenyl]-2-phenyl-ethanone).
Journal: Pharmacology & toxicology
Published: June 06, 2003
Showing 1-8 of 8
Last Updated: 09/26/2026